Olivia Ware Biography and Net Worth

Director of Arcellx

Olivia brings more than 20 years of experience in biotech and pharmaceutical drug development, commercialization, and healthcare management. Most recently, Olivia served as Senior Vice President, BTK Franchise at Principia Biopharma which was acquired by Sanofi in 2020. Prior to that, she was the Senior Vice President for commercial activities at Proteus Digital Health, Inc., a marketing and strategy consultant, and Chief Commercial Officer at CytRx Corporation. Olivia served in a variety of roles of increasing responsibility at Genentech in sales and marketing, managed care and leading global cross-functional teams. Olivia currently serves on the public boards of Revance Therapeutics, Inc., and Ambrx, Inc. Olivia holds an M.B.A. in Finance and Marketing from the University of North Carolina, Chapel Hill, and an A.B. from Davidson College.

How do I contact Olivia C. Ware?: The corporate mailing address for Ms. Ware and other Arcellx executives is , , . Arcellx can also be reached via phone at 240-327-0603 and via email at [email protected]. Learn More on Olivia C. Ware's contact information.
Has Olivia C. Ware been buying or selling shares of Arcellx?: Olivia C. Ware has not been actively trading shares of Arcellx during the last ninety days. Learn More on Olivia C. Ware's trading history.
Who are Arcellx's active insiders?: Arcellx's insider roster includes Jill Carroll (Director), Rami Elghandour (Chairman and Chief Executive Officer), Michelle Gilson (CFO), Christopher Heery (Chief Medical Officer), Kavita Patel (Director), Olivia Ware (Director), and Olivia Ware (Director). Learn More on Arcellx's active insiders.
Are insiders buying or selling shares of Arcellx?: In the last year, insiders at the sold shares 29 times. They sold a total of 852,221 shares worth more than $59,596,182.56. The most recent insider tranaction occured on November, 11th when Director Kavita Patel sold 15,238 shares worth more than $1,614,008.96. Insiders at Arcellx own 6.2% of the company. Learn More about insider trades at Arcellx.
Information on this page was last updated on 11/11/2024.

Olivia C. Ware Insider Trading History at Arcellx

Olivia C. Ware Buying and Selling Activity at Arcellx

Arcellx Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $91.89

$91.20

$96.39

50 Day Range

MA: $88.27

$76.07

$106.53

2 Week Range

Now: $91.89

$46.42

$107.37

Volume

192,556 shs

Average Volume

477,220 shs

Market Capitalization

$4.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Tim Sykes’ Urgent Trade Alert: “Make this move now”

From Timothy Sykes | Ad

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade